Enhanced anti-hepatoma effect of a novel curcumin analog C086 via solid dispersion technology

References

• Al-Tabakha MM. (2010). HPMC capsules: current status and future prospects. J Pharm Pharm Sci 13:428–42.
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, et al. (2007). Bioavailability of curcumin: problems and promises. Mol Pharm 4:807–18.
   PubMed Web of Science ®Google Scholar
• Chen C, Liu Y, Chen Y, et al. (2011). C086, a novel analog of curcumin, induces growth inhibition and down-regulation of NFκB in colon cancer cells and xenograft tumors. Cancer Biol Ther 12:797–807.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu Y, Xu J, et al. (2018). Design and evaluation of nanocomposite microparticles to enhance dissolution and oral bioavailability of andrographolide. Powder Technol 323:219–29.
   Web of Science ®Google Scholar
• Cong W, Shen L, Xu D, et al. (2014). Solid dispersion tablets of breviscapine with polyvinylpyrrolidone K30 for improved dissolution and bioavailability to commercial breviscapine tablets in beagle dogs. Eur J Drug Metab Pharmacokinet 39:203–10.
   PubMed Web of Science ®Google Scholar
• Dou F, Yuan LD, Zhu JJ. (2005). Heat shock protein 90 indirectly regulates ERK activity by affecting Raf protein metabolism. Acta Biochim Biophys Sin (Shanghai) 37:501–5.
   PubMed Web of Science ®Google Scholar
• Fan YJ, Liu Y, Zhang LR, et al. (2017). C0818, a novel curcumin derivative, interacts with Hsp90 and inhibits Hsp90 ATPase activity. Acta Pharm Sin B 7:91–6.
   PubMed Web of Science ®Google Scholar
• Fan YJ, Zhou YX, Zhang LR, et al. (2018). C1206, a novel curcumin derivative, potently inhibits Hsp90 and human chronic myeloid leukemia cells in vitro. Acta Pharmacol Sin 39:649–58.
   PubMed Web of Science ®Google Scholar
• Feng YX, Wang T, Deng YZ, et al. (2011). Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 53:483–92.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Carnero A, Paz-Ares L. (2013). Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol 14:E358–E369.
   PubMed Web of Science ®Google Scholar
• Ghadi R, Dand N. (2017). BCS class IV drugs: highly notorious candidates for formulation development. J Control Release 248:71–95.
   PubMed Web of Science ®Google Scholar
• He Y, Liu H, Bian W, et al. (2019). Molecular interactions for the curcumin-polymer complex with enhanced anti-inflammatory effects. Pharmaceutics 11:442.
   PubMed Web of Science ®Google Scholar
• Health U D o, & Services H. (2018). Bioanalytical method validation, guidance for industry. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry.
   Google Scholar
• Huang X, Xu J, Wen C. (2008). Study on preparation and in vitro dissolution of curcumin-plasdone solid dispersion. Chin J Hosp Pharm 21:1819–1822.
   Google Scholar
• Kaewnopparat N, Kaewnopparat S, Jangwang A, et al. (2009). Increased Solubility, Dissolution and Physicochemical Studies of Curcumin-Polyvinylpyrrolidone K-30 Solid Dispersions. World Acad Sci Eng Technol 55:229–34.
   Google Scholar
• Kaneda Y, Tsutsumi Y, Yoshioka Y, et al. (2004). The use of PVP as a polymeric carrier to improve the plasma half-life of drugs. Biomaterials 25:3259–66.
   PubMed Web of Science ®Google Scholar
• Kelloff GJ, Crowell JA, Hawk ET, et al. (1996). Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl 26:54–71.
   PubMedGoogle Scholar
• Liu W, Zhai Y, Heng X, et al. (2016). Oral bioavailability of curcumin: problems and advancements. J Drug Target 24:694–702.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ye M, Wu Q, et al. (2014). Synthesis and evaluation of 4-arylmethyl curcumin analgues as potent Hsp90 inhibitors. Lett Drug Des Discov 11:993–9.
   Web of Science ®Google Scholar
• Ma Z, Wang N, He H, et al. (2019). Pharmaceutical strategies of improving oral systemic bioavailability of curcumin for clinical application. J Control Release 316:359–80.
   PubMed Web of Science ®Google Scholar
• Reiberger T, Chen Y, Ramjiawan RR, et al. (2015). An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nat Protoc 10:1264–74.
   PubMed Web of Science ®Google Scholar
• Samatar AA, Poulikakos PI. (2014). Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov 13:928–42.
   PubMed Web of Science ®Google Scholar
• Sawicki E, Schellens JH, Beijnen JH, et al. (2016). Inventory of oral anticancer agents: pharmaceutical formulation aspects with focus on the solid dispersion technique. Cancer Treat Rev 50:247–63.
   PubMed Web of Science ®Google Scholar
• Sekikawa H, Nakano M, Arita T. (1978). Inhibitory effect of polyvinylpyrrolidone on the crystallization of drugs. Chem Pharm Bull 26:118–26.
   Web of Science ®Google Scholar
• Sethia S, Squillante E. (2004). Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int J Pharm 272:1–10.
   PubMed Web of Science ®Google Scholar
• Sharma A, Jain CP. (2010). Preparation and characterization of solid dispersions of carvedilol with PVP K30. Res Pharm Sci 5:49–56.
   PubMedGoogle Scholar
• Soga S, Akinaga S, Shiotsu Y. (2013). Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des 19:366–76.
   PubMed Web of Science ®Google Scholar
• Tran P, Pyo YC, Kim DH, et al. (2019). Overview of the manufacturing methods of solid dispersion technology for improving the solubility of poorly water-soluble drugs and application to anticancer drugs. Pharmaceutics 11:132.
   PubMed Web of Science ®Google Scholar
• Wang L, Fan Y, Mei H, et al. (2019). Novel Hsp90 inhibitor C086 potently inhibits non-small cell lung cancer cells as a single agent or in combination with Gefitinib. Cancer Manag Res Volume 11:8937–45.
   PubMed Web of Science ®Google Scholar
• Williams HD, Trevaskis NL, Charman SA, et al. (2013). Strategies to address low drug solubility in discovery and development. Pharmacol Rev 65:315–499.
   PubMed Web of Science ®Google Scholar
• Wilson V, Lou X, Osterling DJ, et al. (2018). Relationship between amorphous solid dispersion in vivo absorption and in vitro dissolution: phase behavior during dissolution, speciation, and membrane mass transport. J Control Release 292:172–82.
   PubMed Web of Science ®Google Scholar
• Wu L, Xu J, Huang X, et al. (2006). Down-regulation of p210 (bcr/abl) by curcumin involves disrupting molecular chaperone functions of Hsp90. Acta Pharmacol Sin 27:694–9.
   PubMed Web of Science ®Google Scholar
• Wu L, Yu J, Chen R, et al. (2015). Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells. Clin Cancer Res 21:833–43.
   PubMed Web of Science ®Google Scholar
• Wu X, Xu J, Huang X, et al. (2011). Self-microemulsifying drug delivery system improves curcumin dissolution and bioavailability. Drug Dev Ind Pharm 37:15–23.
   PubMed Web of Science ®Google Scholar
• Yang K-Y, Lin L-C, Tseng T-Y, et al. (2007). Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 853:183–9.
   PubMed Web of Science ®Google Scholar
• Yang S, Liu G. (2017). Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett 13:1041–7.
   PubMed Web of Science ®Google Scholar
• Ye M, Huang W, Wu WW, et al. (2017). FM807, a curcumin analogue, shows potent antitumor effects in nasopharyngeal carcinoma cells by heat shock protein 90 inhibition. Oncotarget 8:15364–76.
   PubMedGoogle Scholar
• Yu ZT, Ye SQ, Hu GY, et al. (2015). The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. Future Med Chem 7:269–89.
   PubMed Web of Science ®Google Scholar
• Zheng B, Yang L, Wen C, et al. (2016). Curcumin analog L3 alleviates diabetic atherosclerosis by multiple effects. Eur J Pharmacol 775:22–34.
   PubMed Web of Science ®Google Scholar